- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S7655
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| MDA-MB-231 cells | Cytotoxicity assay | 6 days | Cytotoxicity against human MDA-MB-231 cells measured on 6th day by hemocytometry, IC50=0.033 μM | 26988803 | ||
| TNBC cell lines | Growth inhibiton assay | 1 μM | 4 days | CB-839 treatment induced cell loss or decreased cell proliferation by more than 50% in six cell lines (HCC1806, HCC1143, HCC38, MDA-MB-436, MDA-MB-231 and Hs578T); the other six cell lines (HCC1937, HCC70, BT549, MDA-MB-157, MDA-MB-453 and MDA-MB468) were either not affected or had their cell proliferation affected by less than 50% and were called resistant. | 31040181 | |
| MM.1S BzR cells | Function assay | 5 μM | 16 hours | treatment with CB-839 significantly repressed oxygen consumption rate in proteasome-inhibitor resistant cells. | 28415782 | |
| MM.1S cells | Cell viability assay | 72 hours | 28415782 | |||
| U266 cell lines | Cell viability assay | 72 hours | 28415782 | |||
| HT1080 | Cytotoxicity assay | 48 h | IC50 = 44.38 μM | 28174105 | ||
| HCC827 | Cytotoxicity assay | IC50 = 51.42 μM | 28174105 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 100 mg/mL
(174.95 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 571.57 | Formula | C26H24F3N7O3S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1439399-58-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F | ||
| Targets/IC50/Ki |
Glutaminase
(Cell-free assay) 24 nM
|
|---|---|
| In vitro |
Telaglenastat (CB-839) exhibits time-dependent and slowly reversible kinetics. Its IC50 values for glutaminase inhibition following preincubation with rHu-GAC for-1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. This compound has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D. |
| Kinase Assay |
Inhibition of CB-839 on rHu-GAC
|
|
The enzymatic activity is measured in assay buffer containing 50 mM Tris-Acetate pH 8.6, 150 mM K2HPO4 , 0.25 mM EDTA, 0.1 mg/mL bovine serum albumin, 1 mM DTT, 2 mM NADP+ and 0.01% Triton X-100. To measure inhibition by Telaglenastat (CB-839), the inhibitor (prepared in DMSO) is first pre-mixed with glutamine and glutamate dehydrogenase (GDH) and reactions are initiated by the addition of rHu-GAC. Final reactions contains 2 nM rHu-GAC, 10 mM glutamine, 6 units/mL GDH and 2% DMSO. Generation of NADPH is monitored by fluorescence (Ex340/Em460 nm) every minute for 15 minutes on a SpectraMax M5e plate reader. Relative fluorescence units (RFU) are converted to units of NADPH concentration (µM) using a standard curve of NADPH. Each assay plate incorporates control reactions that monitores the conversion of glutamate (1 to 75 µM) plus NADP+ to α-ketoglutarate plus NADPH by GDH. Under these assay conditions, up to 75 µM glutamate is stoichiometrically converts to α-ketoglutarate/NADPH by GDH. Initial reaction velocities are calculated by fitting the first 5 minutes of each progress curve to a straight line. Inhibition curves are fitted to a four-parameter dose response equation of the form: % activity = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)).
|
|
| In vivo |
In the mouse TNBC model, single agent Telaglenastat (CB-839) (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, this compound alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, while its combination with NSC 125973 (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors, resulting in a TGI relative to vehicle control of 100%. |
References |
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | collagen I/collagen III |
|
29019707 |
| Growth inhibition assay | Cell growth |
|
28967864 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04250545 | Recruiting | Leptomeningeal Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
October 26 2020 | Phase 1 |
| NCT02944435 | Completed | Healthy Volunteers |
Calithera Biosciences Inc |
October 2016 | Phase 1 |
| NCT02071927 | Completed | Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL) |
Calithera Biosciences Inc |
March 2014 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.